Business Segment Information - Schedule of Operating Results for the Business Segments (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jul. 31, 2025	Jul. 31, 2025	Jul. 31, 2024
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue		$ 917	$ 637
COSTS AND EXPENSES
General and administrative	$ (58)	(13,781)	(8,854)
Research and development	$ (232)	(12,823)	(4,170)
In-process research and development			(89,861)
Depreciation and amortization		(288)	(225)
Loss on impairment of goodwill		(3,050)
(Loss) income from operations		(29,159)	(102,627)
Reconciliation to loss before income taxes:
Interest income		1,996	2,383
Loss on initial investment in Day Three upon acquisition			(1,633)
Realized gain on available-for-sale securities		178	1,772
Realized loss on investment in equity securities			(46)
Realized gain on investment - Cyclo			424
Unrealized (loss) gain on investment - Cyclo		(5,144)	37
Unrealized (loss) gain on convertible notes receivable, due from Cyclo		(719)	1,191
Unrealized gain on investment - Hedge Funds			63
Recovery of receivables from Cornerstone			31,305
Interest expense		(658)	(248)
Other income, net		310	118
Loss before income taxes		(33,196)	(67,261)
Infusion Technology [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue		93
COSTS AND EXPENSES
(Loss) income from operations		(3,815)	(675)
Rental – Third Party [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue		197	174
Rental Related Party [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue		112	108
Product Revenue [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue		515
Infusion Technology revenue [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue			355
Health Care [Member]
COSTS AND EXPENSES
(Loss) income from operations		(25,294)	(102,032)
Real Estate [Member]
COSTS AND EXPENSES
(Loss) income from operations		(50)	80
Infusion Technology revenue [Member]
COSTS AND EXPENSES
Cost of product revenue		(106)	(154)
Product Revenue [Member]
COSTS AND EXPENSES
Cost of product revenue		(28)
Healthcare [Member]
COSTS AND EXPENSES
General and administrative		(13,165)	(8,338)
Research and development		(12,568)	(3,668)
In-process research and development			(89,861)
Depreciation and amortization		(48)	(165)
Loss on impairment of goodwill
(Loss) income from operations		(25,294)	(102,032)
Healthcare [Member] | Infusion Technology [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue
Healthcare [Member] | Rental – Third Party [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue
Healthcare [Member] | Rental Related Party [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue
Healthcare [Member] | Product Revenue [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue		515
Healthcare [Member] | Infusion Technology revenue [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue
Healthcare [Member] | Infusion Technology revenue [Member]
COSTS AND EXPENSES
Cost of product revenue
Healthcare [Member] | Product Revenue [Member]
COSTS AND EXPENSES
Cost of product revenue		(28)
Infusion Technology [Member]
COSTS AND EXPENSES
General and administrative		(320)	(374)
Research and development		(255)	(502)
In-process research and development
Depreciation and amortization		(177)
Loss on impairment of goodwill		(3,050)
(Loss) income from operations		(3,815)	(675)
Infusion Technology [Member] | Infusion Technology [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue		93
Infusion Technology [Member] | Rental – Third Party [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue
Infusion Technology [Member] | Rental Related Party [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue
Infusion Technology [Member] | Product Revenue [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue
Infusion Technology [Member] | Infusion Technology revenue [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue			355
Infusion Technology [Member] | Infusion Technology revenue [Member]
COSTS AND EXPENSES
Cost of product revenue		(106)	(154)
Infusion Technology [Member] | Product Revenue [Member]
COSTS AND EXPENSES
Cost of product revenue
Real Estate [Member]
COSTS AND EXPENSES
General and administrative		(296)	(142)
Research and development
In-process research and development
Depreciation and amortization		(63)	(60)
Loss on impairment of goodwill
(Loss) income from operations		(50)	80
Real Estate [Member] | Infusion Technology [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue
Real Estate [Member] | Rental – Third Party [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue		197	174
Real Estate [Member] | Rental Related Party [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue		112	108
Real Estate [Member] | Product Revenue [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue
Real Estate [Member] | Infusion Technology revenue [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total revenue
Real Estate [Member] | Infusion Technology revenue [Member]
COSTS AND EXPENSES
Cost of product revenue
Real Estate [Member] | Product Revenue [Member]
COSTS AND EXPENSES
Cost of product revenue